Does high-dose extended course cyclophosphamide and methylprednisolone pulse therapy have a role in the management of systemic sclerosis-related interstitial lung disease?

Rheumatology (Oxford). 2016 Dec;55(12):2273-2275. doi: 10.1093/rheumatology/kew362. Epub 2016 Oct 15.

Authors

Giuseppina Abignano^{1

2}, Lesley-Anne Bissell^{1

2}, Paul Emery^{1

2}, Francesco Del Galdo^{1

2}, Maya H Buch^{3

2}

Affiliations

¹ Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds.
² NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
³ Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds m.buch@leeds.ac.uk.

PMID: 27744357
DOI: 10.1093/rheumatology/kew362

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Cyclophosphamide / administration & dosage*
Disease Management*
Dose-Response Relationship, Drug
Drug Therapy, Combination
Female
Glucocorticoids / administration & dosage
Humans
Immunosuppressive Agents / administration & dosage
Lung Diseases, Interstitial / drug therapy*
Lung Diseases, Interstitial / etiology
Male
Methylprednisolone / administration & dosage*
Middle Aged
Scleroderma, Systemic / complications*
Scleroderma, Systemic / drug therapy

Substances

Glucocorticoids
Immunosuppressive Agents
Cyclophosphamide
Methylprednisolone